In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?

ABSTRACT: Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic control of this virus the development of an effective prophylactic or therapeutic vaccine becomes a must. The coronavirus disease 19 (COVID-19) pandemic led to auspicious vaccine development against severe acute respiratory syndrome coronavirus-2 (SARS-CoV

SUBMITTER: Echeverria N 

PROVIDER: S-EPMC8568586 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature